Bioventix delivered 14% adjusted PBT and EPS growth despite the end of their NT-proBNP contract and the resultant loss of £1.2 in royalties (13% of FY 22 PBT), with adjusted pre-tax profit some £1.5m (18%) above expectations at £9.5m. This was driven by 17% revenue growth in H2 (vs -8% in H1), indicative of a return to pre-pandemic testing volumes and the rising influence of troponin on growth; resulting in FY 2022 revenues +7% to £11.7m. Our analysis suggests that adjusted EBIT increased 14% (5 ....
